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บทคดัยอ่ 
วตัถปุระสงค:์ เพื่อตรวจสอบอตัราการกลายเป็นโรคไตเรือ้รงัเป็นระยะ 4 ในผูป้่วยโรค
ไตเรือ้รงัระยะ 3a และ 3b และการจดัการดแูลรกัษาผูป้่วยโรคไตเรื้อรงัในระยะ 3a และ 
3b วิธีการศึกษา: การศึกษานี้ เป็นการศึกษาย้อนหลัง  3 ปี จากฐานข้อมูล
อเิลก็ทรอนิกสข์องโรงพยาบาลส่งเสรมิสุขภาพต าบล (รพ.สต.) ในจงัหวดันครราชสมีา 
จ านวน 12 แห่ง โดยคดัเลือกผูป้่วยโรคเบาหวานและ/หรอืความดนัโลหิตสูงที่มอีายุ
ตัง้แต่ 18 ปีขึ้นไป และเป็นโรคไตเรื้อรงัระยะ 3a และ 3b ก่อนหน้าหรือระหว่าง
ปีงบประมาณ 2556 และติดตามจนสิ้นสุดการศึกษาในปีงบประมาณ 2558 ผล
การศึกษา: ในปี 2556 มผีูป้่วยระยะ 3a และ 3b จ านวน 162 และ 142 คนตามล าดบั
ทีม่กีารด าเนินโรคเป็นระยะ 4 จ านวน 6 คน (ร้อยละ 3.70) และ 14 คน (ร้อยละ 9.86) 
มรีะยะเวลาทีโ่รคไตยงัไม่กลายเป็นระยะ 4 เท่ากบั 2.42 ปี ในปี 2558 มผีูป้่วยระยะ 3 
จ านวนรวม 142 คน ซึ่งพัฒนาเป็นระยะ 4 จ านวน 20 คนส่วนอีก 122 คนยงัไม่
เปลี่ยนแปลง ในด้านการจัดการดูแลผู้ป่วยที่กลายและไม่กลายเป็นระยะ 4 พบว่า 
สามารถควบคุมระดบัน ้าตาลในเลอืดหลงัอดอาหารให้อยู่ในช่วง 80 ถงึ 130 มก% ได้
ทุกครัง้ (ร้อยละ 7.69 และ 6.00)  ควบคุม HbA1c ให้น้อยกว่าร้อยละ 7 ได้ทุกครัง้ 
(รอ้ยละ 23.08 และ 40.00) และควบคุมความดนัโลหติให้ไม่เกนิ 140/90 มม.ปรอทได้
ทุกครัง้ (รอ้ยละ 35.00 และ 40.16) จ านวนผูป้่วยความดนัโลหติสูงที่โรคไตแย่ลงได้รบั 
angiotensin-converting enzyme inhibitors (ACEIs) หรอื angiotensin receptor 
antagonists (ARBs) น้อยกว่าผู้ป่วยที่ไม่มีการกลายของโรค (ร้อยละ 25.00 และ 
51.26) ซึ่งผลนี้เหมือนกบัผู้ป่วยโรคเบาหวานที่มี micro-albuminuria และได้รบัยา 
ACEIs หรอื ARBs (ร้อยละ 0 และ 2.00) และผูป้่วยอายุ 50 ปีขึน้ไปที่ได้รบั statins 
(รอ้ยละ 40.00 และ 58.82) ผูป้่วยระยะ 3a ไดร้บัการตดิตามการท างานของไตครบทุก
รายอย่างน้อยปีละครัง้ แต่ผูป้่วยระยะ 3b และ 4 ส่วนใหญ่ได้รบัการตดิตามแต่ไม่ครบ
ตามแนวทางการรกัษา ผู้ป่วยทุกรายไม่ได้รบัการติดตามภาวะซดี ภาวะกรดเกนิใน
เลอืดหรอืความผดิปกตขิองเกลอืแรแ่ละกระดูก สรุป: ผูป้่วยโรคไตเรื้อรงัที่ไม่กลายไป
เป็นระยะ 4 มีแนวโน้มที่จะได้รบัการจดัการดูแลที่ดีกว่าผู้ป่วยที่กลายเป็นระยะ 4 
อย่างไรกต็ามผูป้่วยโรคไตเรื้อรงัทุกรายยงัได้รบัการดูแลไม่ครบตามมาตรฐาน ควรมี
การก าหนดนโยบายเกี่ยวกับระบบการจดัการดูแลรกัษาผู้ป่วยโรคไตเรื้อรงัอย่างมี
ประสทิธผิลโดยสหสาขาวชิาชพีและปฏบิตัใิหบ้รรลุผลส าเรจ็ต่อไป  
ค าส าคญั: โรคไตเรือ้รงั, การด าเนินของโรค, การจดัการดแูลรกัษาโรค, โรคเบาหวาน, 
โรคความดนัโลหติสงู  
 
 
 
Abstract 
Objective: To investigate the rate of progression to stage 4 chronic kidney 
disease (CKD) in patients with CKD stage 3a and 3b, and the management 
they received. Method: In this 3-year retrospective study, the electronic 
databases of 12 health-promoting hospitals in Nakhon Ratchasima Province 
were used. Patients with diabetes and/or hypertension who were at the age of 
18 years or over and had CKD stage 3a and 3b before or during the fiscal year 
of 2013 were recruited and followed up until the end of the fiscal year of 2015. 
Results: In 2013, 162 and 142 patients experienced CKD stage 3a and 3b, 
respectively, but only 6 (3.70%) and 14 (9.86%) of them progressed to stage 4. 
The progression–free period of CKD stage 4 was 2.42 years. In 2015, 20 of 
142 stage 3 CKD patients progressed to stage 4, whereas 122 did not. In 
terms of disease management for the patients with and without the progression 
their fasting blood sugar was within the range of 80 – 130 mg% (7.69% vs. 
6.00%), HbA1c under 7% (23.08% vs. 40.00%) and blood pressure at 140/90 
mmHg or lower (35.00% vs. 40.16%). The number of hypertensive patients 
with the progression who received angiotensin-converting enzyme inhibitors 
(ACEIs) or angiotensin receptor blockers (ARBs) was lower than those without 
the progression (25.00% vs. 51.26%). This result was similar to diabetic 
patients with micro-albuminuria who took either ACEIs or ARBs (0% vs. 2.00%) 
and patients aged 50 years or over who received statins (40.00% vs. 58.82%). 
For laboratory monitoring, all stage 3a patients were tested for the renal 
function at least once a year, but most patients with stage 3b and 4 were not 
fully monitored according to the guidelines. None of them were monitored for 
anemia, acidosis, or mineral and bone disorders. Conclusion: CKD patients 
with no progression to stage 4 were more likely to receive a better 
management than those with the progression. All patients however did not 
obtain the complete standard care. A policy on the effective management of 
CKD patients by a multidisciplinary team should be developed and 
implemented.  
Keywords: chronic kidney disease, disease progression, disease 
management, diabetes, hypertension  
 
Introduction 
In chronic kidney diseases, there are histological and/or 
physiological damages leading to the kidneys impaired 
functions. Permanent damage takes a considerably long 
duration to occur. Based on the clinical guideline of KDIGO, 
chronic kidney disease (CKD) is defined as the decrease in 
kidney function or an abnormality in kidney structure for 
more than 90 days.1 CKD is a complication of diabetes 
mellitus and hypertension. Previous studies indicate that 
most patients with these two chronic diseases were not 
aware of CKD as the consequence of their illnesses.2-6 This 
could be att ributable to the fact that CKD is usually 
asymptomatic at the early stage even with a decrease of 
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50% of kidney function.7 A limited availability of the annual 
physical examination could result in  a delayed detection of 
CKD. In addition, with an increasing trend of the incidents of 
diabetes and hypertension new cases, unavailability of a 
clear guideline to manage these CKD patients could result in 
delayed diagnosis and treatment.  
At present, hospitals at all levels of care have been 
encountering the increasing number of patients with diabetes 
and hypertension, and hence CKD patients as a result. 
Clinics and referral systems to take care of patients with 
diabetes, hypertension and CKD have been developed 
nationwide. In Thailand, a given community hospital which is 
a district hospital supervises and forms a network of referral 
system with a number of health-promoting hospitals within 
the district. At the chronic disease clinic of Chock Chai 
Community Hospital, diabetes and/or hypertension 
accounted for 66.27%, 63.62% and 75.19% of cases 
referred from the health-promoting hospitals. In the fiscal 
year of 2014, there were 1,182, 121 and 40 patients with 
CKD stage 3, 4 and 5, respectively. These numbers were 
unexpectedly low. In the fiscal year of 2014, CKD clinic was 
set at Chok Chai Hospital as guided by the service plan 
policy of the Ministry of Public Health.9 However, only 100 
cases of CKD of all patients referred from health-promoting 
hospitals were found. Therefore, it was evident that a large 
portion of CKD patients with or without diagnosis were still 
treated at the health-promoting hospitals.  
Patients with diabetes and/or hypertension should be 
assessed for kidney complications at the early stage and 
provided with standard managements for all stages of CKD. 
These managements include renal function monitoring and 
management of anemia10, electrolyte and mineral 
imbalance11, hypertension12, blood glucose control, sodium 
control, smoking, drug- or substance-induced kidney injury, 
and the use of angiotensin-converting enzyme inhibitors 
(ACEIs), angiotensin receptor blockers (ARBs) and 
statins.1,2,13 Standard treatments could have prevented renal 
complications and other complications as a result of CKD. 
The most common cause of death associated with CKD 
is cardiovascular diseases (CVDs). In patient with stage 3 
CKD or higher in particulr, the risk of CVDs increased by 
43%.13 Therefore, the progression from the early to late 
stage of CKD is of a great concern . A better understanding 
could help manage the disease and prevent the 
complications effectively. This study aimed to determine the 
rate of progression to stage 4 CKD of patients with stage 3a 
and 3b. How well the disease management was done was 
also determined. These management components included 
risk factor control, drug therapy to slow the progression and 
prevent cardiovascular complications, and renal function and 
related complications monitoring. The findings could be used 
to improve the service for patients with chronic kidney 
disease.  
 
Methods 
 
In this study, a retrospective cohort design was used. 
Data from the electronic medical records of 12 health-
promoting hospitals under the supervision of Chok Chai 
Hospital, Nakhon Ratchasima Province, were used. 
Participants were diabetes and/or hypertension with an age 
of 18 years or older who were treated during the fiscal years 
of 2013 to 2015. Participants were selected using 
convenience sampling method. Since there was a limited 
number of patients with CKD stages 3 at these health-
promoting hospitals, all patients eligible for study criteria 
were recruited. Participants had to have stage 3a or 3b CKD 
which were confirmed by the serum creatinine (SCr) level of 
at least two measures at least 90 days apart, before or 
within the fiscal year of 2013. Their estimated glomerulus 
filtration rate (eGFR) was calculated using the formula of 
CKD-EPI (CKD epidemiology collaboration).14 Participants’ 
stages of CKD were classified based on the definition of 
CKD stages provided by KDIGO (2012).1 No renal 
histological abnormality was used to classify CKD stages. 
Based on KDIGO (2012), CKD stage 3a and 3b were those 
with eGFR of 45.00 - 59.99 and 30.00 - 44.99 mL/min/1.73 
m2, respectively.  
In their electronic medical records, these patients were 
followed until either the development of CKD stage 4 or the 
end of follow-up period which was the end of the fiscal year 
of 2015 (September 30, 2015). For exclusion criteria, we 
excluded patients with acute kidney injury, CKD stage 4 or 5, 
renal replacement therapy, and incomplete data. Patients 
who were referred to other hospitals and could not be 
followed were also excluded. This study was approved by 
the ethics committee of Mahasarakham University (approval 
number: 007/2559, approval date: March 28, 2016).  
The patient’s data obtained were gender, age, body 
weight, height, illnesses, smoking history, blood pressure, 
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serum creatinine (SCr), hemoglobin, serum bicarbonate, 
serum calcium, serum phosphate, parathyroid hormone, 
HbA1c, FBS, lipid profile, and micro-albuminuria. Their 
history of medication use and adverse drug events related to 
ACEIs, ARBs or statins was also obtained.  
The management of CKD patients was identified 
according to the KDIGO’s Clinical practice guideline for the 
evaluation and management of chronic kidney disease1 and 
the clinical practice recommendation for the evaluation and 
management of chronic kidney disease in adults 2015 of the 
Nephrology Society of Thailand.3 How well the patients were 
managed regarding risk factor control, drug therapy to slow 
the kidney failure progression and prevent cardiovascular 
complications, and the monitoring of renal function and 
related complications were identified. For risk factor control, 
proportions of patients with blood pressure of less than 
140/90 mmHg, HbA1c of less than 7%, and fasting blood 
sugar of less than 130 mg% were identified. For drug 
therapy to slow the kidney failure progression and prevent 
cardiovascular complications, proportions of patients 
receiving ACEIs or ARBs were identified. ACEIs or ARBs 
should be considered the first-line therapy for hypertensive 
or diabetic patients with micro-albuminuria (albumin of 20 
mg/L or higher). In addition, statins should be given to all 
patients with 50 years of age or older who had CKD stage 
3a or higher, or patients who were 18 to 49 years old with at 
least one of the following risk factors; diabetes, coronary 
revascularization, ischemic stroke, and myocardial infarction. 
Each of these risk factors contributed to at least 10% of 
Framingham risk score.  
In terms of the monitoring of renal function and related 
complications, type and frequency of laboratory tests were 
scheduled as shown in Table 1.  
    
 
 Table 1  Monitoring schedule for CKD complications.  
Laboratory test 
Number of monitoring per year by CKD stage  
3a 3b 4 
Serum creatinine (SCr) 1 2 3 
Hb (with anemia)  4  
Hb (without anemia) 1 2 2 
Ca2+, PO4, bicarbonate 1 - 2 2 - 4 2 - 4 
Parathyroid hormone Base line (1) 1 - 2 1 - 2 
 
 
Statistical analysis  
All analyses were carried out using the software program 
STATA version 14. For time-to-event analysis, Kaplan-Meier 
survival analysis was conducted to determine progression-
free proportions over time of the patients with stage 3a and 
3b. Difference between the two curves was compared using 
Log-rank test. Progression-free proportions over time of all 
stage 3 CKD patients were also determined. The first day of 
stage 3a and 3b was the day of the annual check-up in the 
fiscal year of 2013. Each patient was followed up until the 
progression to stage 4 CKD, loss to follow-up, or the end of 
the study (September approaching the end of the study 
(September 30, 2015), whichever came first.  
Descriptive statistics, frequency with percentage and 
mean with standard deviation, were also used to present 
demographic and health status information at baseline, and 
the management of the patient care in the fiscal year of 
2015. Frequency with percentage was presented for 1) 
proportions of patients who had blood pressure under control 
(at all visits, or not all visits), and fasting blood sugar and 
HbA1c under control (in all tests, in some tests, none of the 
tests, or data not available), 2) proportions of patients who 
were treated with and without ACEIs, ARBs, or statins, 3) 
proportions of patients with renal function monitoring, and 4) 
proportions of patients with monitoring of renal function 
related complications.  
   
Results  
 
Of the 3,552 patients screened, 304 patients were 
eligible for the study. Of the 304 patients eligible, there were 
slightly more patients with CKD stage 3a (53.29%) than 
stage 3b (46.71%). About three-fourths were female (75.00). 
The majority had the age of 70 years or older (55.59%)) with 
a mean age of 71.60 years. The majority had hypertension 
(58.88%) followed by diabetes and hypertension (39.47%). 
Their eGFR moderately low with a mean of 45.43 
mL/min/1.73 m2.  
 
Risk and rate of progression to CKD stage 4  
As expected, the risk of progressing to CKD stage 4 in 
patients with stage 3a was lower than those with stage 3b. 
Among 162 patients with CKD stage 3a and 142 with stage 
3b, 6 (3.70%) and 14 (9.86%) of them had progressed to 
CKD stage 4, respectively, with an overall risk of 6.58% (20 
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of 304 patients). In terms of incidence rate, 142 patients with 
CKD stage 3b contributed 4,008.19 person-months. With 14 
patients progression to stage 4, an incidence rate of 0.35 per 
100 person-month in CKD patients with stage 3b was found. 
Among those with CKD stage 3a, an incidence rate of 
progressing to stage 4 of 0.13 per 100 person-months was 
found. The overall rate of progression to stage 4 was 0.23 
per 100 person-months (Table 3).  
 
 Table 2  Demographic and clinical status of patients 
with CKD stage 3a and 3b (N = 304).  
Characteristics  N (%)  
Gender  
male  
female 
 
76 (25.00) 
228 (75.00) 
Age (years), (mean ± SD)  71.60 ± 10.49 
Age group (years)  
41 – 50  
51 – 60  
61 – 70  
> 70  
 
10 (3.29) 
36 (11.84) 
89 (29.28) 
169 (55.59) 
Estimated glomerular filtration rate (eGFR) (mL/min/m2), mean ± 
SD 
45.43 ± 7.63 
CKD stage*  
3a  
3b  
 
162 (53.29) 
142 (46.71) 
Comorbidity  
Diabetes  
Hypertension  
Diabetes and hypertension  
 
5 (1.65) 
179 (58.88) 
120 (39.47) 
   * eGFR by CKD stage: 3a = eGFR 45.00 - 59.99 mL/min/m2, 3b = 44.99 - 30.00 mL/min/m2, 4 = 
29.99 - 15.00 mL/min/m2   
 
 Table 3   Risk and rate of progression to CKD stage 4 
in CKD patients with stage 3a and 3b from 2013 to 2015 (N = 
304).  
Progression to CKD stage 4 
CKD stage 3a 
(n = 162) 
CKD stage 3b 
(n = 142) 
Overall 
(N = 304) 
Risk: n (%) 6 (3.70)  14 (9.86)  20 (6.58) 
Rate: per 100 patient-months  0.13 0.35 0.23 
 
 
Once the risk was considered based on the time-to-event 
basis, the risk of developing CKD stage 4 in patients with 
CKD stage 3a was significantly lower than those with stage 
3b (P-value = 0.029, log-rank test) (Figure 1). At 12 and 24 
months, patients with CKD stage 3a had pregression-free 
proportions of 98.77% (95%CI: 95.15-99.69) and 96.91% 
(95%CI: 92.74-98.70), respectively. With higher chances of 
becoming CKD stage 4 than those with stage 3a, patients 
with CKD stage 3b had progression-free proportions of 
93.66% (95%CI: 88.17-96.65) and 90.14% (95%CI: 83.92-
94.04), at 12 and 24 months, respectively.  
 
 
 Figure 1  Kaplan-Meier curves depicting the progression-
free survival to CKD stage 4 in patients with CKD stage 3a and 
3b with statistical significance (P-value = 0.029, Log-rank test) 
(N = 304).  
 
With all 304 CKD stage 3 patients, the progression to 
stage 4 was found in 6.58%. With 8,658.11 person-months, 
the incidence rate of 0.25 per 100 person-months was found. 
They had a progression-free proportions of 96.38% (95% CI: 
93.56-97.98) and 93.75% (95% CI: 90.38-95.97), at 12 and 
24 months, respectively. The progression-free period of 
29.06 months (2.42 years) was found (Figure 2).  
   
 
 
  
 Figure 2  Kaplan-Meier curves depicting the progression-
free survival to CKD stage 4 in all patients with CKD stage 3 (N 
= 304).  
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The progression to stage 4 CKD among patients with 
CKD stage 3a and 3b   
In the fiscal year of 2013, there were 304 patients with 
CKD stage 3a and 3b combined. At the end of 2015, 20 of 
them had their kidney progressed to stage 4, specifically 17 
cases in 2014 and 3 cases in 2015. It was found that 122 
patients (42.51%) did not experience the progression to 
stage 4 CKD 4 at the end of 2015. There were 144 patients 
(50.17%) with no serum creatinine to determine the 
progression at the end of 2015.  
 
 Table 4  The progression to stage 4 of patients with CKD 
stage 3a and 3b from the fiscal year of 2013 to 2014 and 
2015.  
 
N (%) by fiscal year 
2014 
(N = 304) 
2015 
(N = 287)* 
Progression to stage 4  17 (5.59) 3 (1.05) 
Among CKD stage 3a 4 2 
Among CKD stage 3b 13 1 
No progression to CKD stage 4 158 (51.97) 122 (42.51) 
No serum creatinine to determine the 
progression** 
124 (40.79) 144 (50.17) 
Loss to follow-up  5 (1.64) 18 (6.27) 
 * Seventeen patients had developed to stage 4 CKD in the fiscal year of 2014.  
 ** Patients had been treated but with no annual check-up. 
 
 
The performance of the management to slow the 
progression to stage 4 CKD in the fiscal year of 2015   
Based on the information in the fiscal year of 2015, risk 
factor control, drug therapy to slow the progression and 
prevent cardiovascular complications, and renal function and 
related complications monitoring were evaluated and the 
results were as follows.  
In terms of the adequacy of controlling risk factors of 
CKD progression, among 20 and 122 patients with and 
without progression to stage 4 CKD in the fiscal year of 
2015, fasting blood sugar (FBS) could be controlled within 
the target only by 7.69% and 6.00% of the patients, 
respectively (Table 5). Only 23.08% and 40.00% of the 
patients had their HbA1c under control, respectively. In 
addition, blood pressure was well controlled by 35.00% and 
40.16% of patients who did and did not experience stage 4 
CKD, respectively.  
Regarding the effort to slow the kidney function 
impairment and prevent cardiovascular complications, 
25.00% and 51.26% of the patients with and without 
progression to stage 4 CKD, respectively, received ACEs or 
ARBs (Table 6). Among patients with micro-albuminuria, 
0.00% and 2.00% of them received ACEs or ARBs. 
However, almost all patients were not tested for micro-
albuminuria (100.00% and 96.00% in patients with and 
without progression, respectively). Regarding the need of 
statins to prevent cardiovascular diseases, among patients 
with 50 years of age or older, 40.00% and 58.82% of 
patients with and without progression to stage 4 CKD were 
given a statin. In addition, the only one diabetes patients 
with age of 18 to 49 years old who did not develop stage 4 
CKD received a statin (100.00%).  
In terms of the adequacy of monitoring the complications 
among CKD patients, patients with stages 3a, 3b and 4 
should be monitored for their renal function at least 1, 2 and 
3 times a year, respectively. In the fiscal year of 2015, all 
patients with stage 3a had their renal function tested for at 
least one time (100.00%) (Table 7). For 42 patients with 
stage 3b, one of them (2.38%) had their renal function tested 
at least two times while the rest 97.62% had the test once. 
Among 20 patients with stage 4, all of them (100.00%) had 
their renal function tested at least once or twice. In terms of 
anemia, parathyroid hormone level and the balance of bone 
minerals, none had these measures monitored.   
 
 
 Table 5  Risk factor control to slow the progression to 
stage 4 CKD in the fiscal year of 2015.  
Risk factor control 
N (%) by progression status (N = 142)  
Progressing to stage 4 
Not progressing to 
stage 4 
(n = 20) (n = 122)  
   
1. Blood pressure control (SBP/DBP  140/90 mmHg)#  
- under control in all visits  7 (35.00) 49 (40.16) 
- under control in some visits 13 (65.00) 73 (59.84) 
2. FBS control (80 - 130 mg%)* n = 13 n = 50 
- under control in all tests   1 (7.69) 3 (6.00) 
- under control in some tests 11 (84.62) 39 (78.00) 
- not under control in all tests 1 (7.69) 3 (6.00) 
- data of FBS measures not available  - 5 (10.00) 
3. HbA1c control (< 7%)*             n = 13 n = 50 
- HbA1c under control in all tests  3 (23.08) 20 (40.00) 
- under control in some tests - 1 (2.00) 
- not under control in all tests 5 (38.46) 18 (36.00) 
- data of HbA1c measures not available 5 (38.46) 11 (22.00) 
  # 
Patients with diagnosis of hypertension or anti-hypertensive medications. 
   * Patients with diagnosis of diabetes or glucose-lowering medications.  
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 Table 6  Drug therapy to slow kidney function impairment 
and prevent cardiovascular complications in the fiscal year of 
2015. 
Drug therapy to slow kidney function impairment 
and prevent cardiovascular complications 
N (%) by progression status (N = 142) 
Progressing to  
stage 4 
Not progressing  
to stage 4 
(n = 20) (n = 122)  
   
1. Patients receiving ACEIs or ARBs#   
1.1 Patients with hypertension  n = 20 n = 119 
- had received the drug  5 (25.00) 61(51.26) 
- had never received the drug 15 (75.00) 58(48.74) 
1.2 Patients with diabetes and micro-
albuminuria 
n = 13 n = 50 
- had received the drug - 1 (2.00) 
- had never received the drug - 1 (2.00) 
- data of micro-albuminuria measures not 
available 
13 (100) 48 (96.00) 
   
2. Patients receiving statins#    
2.1 Patients with age of 50 years of older  n = 20 n = 119 
- had received the drug 8 (40.00) 70 (58.82) 
- had never received the drug 12 (60.00) 49 (41.18) 
2.2 Patients with age of 18 – 49 years    
2.2.1 With diabetes n = 0 n = 1 
- had received the drug - 1 (100.00) 
- had never received the drug - - 
2.2.2 Without diabetes  n = 0 n = 2 
- no need for the drug because of 
10-year coronary risk <10% 
- 2 (100.00) 
# The patient had received drug(s) in the groups of AEIs, ARBs or statins one time or more in the fiscal year 
of 2015.  
Note: ACEIs = angiotensin-converting enzyme inhibitors; ARBs = angiotensin receptor blockers.  
 
 Table 7  Monitoring of the renal function, anemia, 
parathyroid level, acid-base balance and bone mineral balance 
in the fiscal year of 2015.  
Measures to monitor 
N (%) by progression status  
(N = 142) 
Progressing to 
stage 4 
Not progressing  
to stage 4 
(n = 20) (n = 122) 
   
1. Renal function monitoring based on serum creatinine  
Stage 3a (≥ 1 time per year)  n = 80 
Complete  - 80 (100) 
Incomplete  - - 
Stage 3b (≥ 2 times per year)  n = 42 
Complete  - 1 (2.38) 
Incomplete  - 41 (97.62) 
Stage 4 (≥ 3 times per year)   
Complete  - - 
Incomplete  20 (100) - 
2. Anemia monitoring based on hemoglobin level  n = 20 n = 122 
Complete  - - 
Incomplete  - - 
Not receiving any monitoring  20 (100) 122 (100) 
3. Bone mineral balance monitoring based on serum calcium and phosphate 
Not receiving any monitoring  20 (100) 122 (100) 
4. Parathyroid hormone level monitoring     
Not receiving any monitoring  20 (100) 122 (100) 
5. Acid-base balance monitoring based on serum bicarbonate 
Not receiving any monitoring  20 (100) 122 (100) 
Discussions and Conclusion  
In this retrospective cohort study, 3.70% and 9.86% of 
patients with CKD stage 3a and 3b, respectively, had 
progressed to stage 4. They had a progression-free duration 
of 2.42 years. At 12 and 24 months, the risks of progression 
to stage 4 were 3.62% and 6.255%, respectively. This 
finding was different from the study of Mikkata and 
colleagues which found the progression-free duration of only 
1.9 years but a higher progression risk to stage 4 of 4%. 
They also found the risk of progression at 12 and 24 months 
of 4% and 15%, respectively.15  
In terms of healthcare service provided at the health-
promoting hospitals, these patients with stage 3 CKD in our 
study received the care from a multidisciplinary team 
consisting of a physician, three nurse practitioners, and a 
pharmacist. The service has been revised for improvement 
annually by the multidisciplinary team and healthcare 
providers at the health-promoting hospitals. Previous report 
indicated that multidisciplinary care resulted in a 38% lower 
risk of all-cause mortality (OR 0.62, P-value = 0.01) and a 
41% lower risk of renal replacement therapy (OR 0.59, P-
value = 0.02) than the usual care with a statistical 
significance.16  
We found that diabetic patients with stage 4 CKD 
achieved a glycemic control based on HbA1c level in only 
23.08% which was lower than those with no progression to 
stage 4 (40.00%). This could be attributable to the lack of 
concern about risk factor control, and non-adherence to diet 
control and medication use. The evaluation of the outcome 
of HbA1c was somewhat limited and comparisons between 
different groups of patients could be biased. This was 
because, with a budget constraint, the measurement of 
HbA1 level could be done only in some patients.  
The study of Chan and co-workers in China found that 
26% of the patients could achieve glycemic control based on 
HbA1c level.17 Compared with our study, this proportion was 
higher than our patients with stage 4 CKD but lower than 
those with no such progression. This discrepancy could be a 
result of different study design. In Chan’s study, their 
prospective design was used to compare efficacy of a 
program compared with the usual care to type 2 diabetic 
patients; while our study used a retrospective data analysis.  
In this study, to obtain the complete data of glycemic 
control was considerably challenging. At health-promoting 
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hospitals, fasting blood sugar level was usually measured 
using the finger-tip testing which is somwhat less reliable 
than the forearm testing. In addition, a follow-up system on 
the patients who missed the annual check -up was not in 
place. Blood sugar levels were reported with different 
channels, especially when they were not transmitted through 
the electronic system which could lead to the incomplete 
data of blood sugar levels. 
In the fiscal year of 2015, among patients with the 
progression to stage 4 CKD, 35.00% had their blood 
pressure under control at all visits while 40.16% of those 
with no progression did. Our finding was different from the 
studies of Mikkata and collagues15 and Chan and co-
workers17 which found only 2.60% and 27.00%, respectively. 
One of the discrepancy could be attributable to the target 
blood pressure used in different studies. While out study 
used a cut-off of 140/90 mmHg; these two studies used a 
more strict cut-off of 130/80 mmHg.15,17 With differences in 
economic systems, socioeconomic status and dietary 
behavior of the patients in various studies, one could expect 
blood pressure control to be different.  
Patients with hypertension should be given ACEIs or 
ARBs as the first-l ine therapy18 to decellerate the renal 
function impairment.12 In our study, unfortunately, only 
25.00% of hypertensive patients with progression to stage 4 
CKD received these drugs which was lower than those with 
no progression (51.26%). In the study of Mikkata and 
colleagues, as high as 55.9% of the patients were given 
ACEIs.15 A low proportion of patients receiving ACEIs or 
ARBs in our study could be due to the fact that not all 
patients treated at the health -promoting hospitals were 
treated by the physician. On the other hand, all patients in 
previous studies were treated by the physician at the 
hospital. In addition, the JNC 8 guideline (2014) 
recommended ACEIs or ARBs as the first-line drugs for 
hypertensive patients with CKD. However, patients with 
normal kidney function could be treated with a variety anti-
hypertensive drugs.18 Typically, diuretics was recommended 
as the first-line drug by all previous guidelines. Furthermore, 
recommendations for patients with CKD were relatively 
inconclusive. Therefore, the use of ACEIs or ARBs was not 
fully encouraged and hence the proportion of patients who 
were given these drugs in our study was low.  
In our study, patients with contra-indications to use 
ACEIs or ARBs were not excluded. The contra-indications 
included adverse reactions to the drugs, an increase in SCr 
or a decrease in eGFR of more than 30% from baseline, and 
a serum potassium level of more than 5.5 millimoles per liter. 
Since these drugs could cause acute kidney injury, 
hypertensive patients with CKD should be monitored for SCr 
and serum potassium at 2 to 4 weeks after the initiation of 
the drug.1,3  
The issue of using ACEIs or ARBS to slow micro-
albuminuria progression among patients with diabetes was of 
a great concern. In the fiscal year of 2015, none of diabetic 
patients with micro-albuminuria with the progression to stage 
4 CKD were given ACEIs or ARBS while 2% of those with 
no progression to stage 4 CKD received the drug. This 
finding could be somewhat biased since the reports of micro-
albuminuria data were limited. This drawback could be due 
to a lack of the clear protocol to manage these CKD 
patients, no follow-up system for patients missing their 
annual check-up, a lack of patient’s concern to get their 
renal function checked, and the incomplete electronic 
reports. To better determine the progression of the disease 
and the management performance, a well established 
protocol or guideline to manage these patients should be in 
place. The progression of kidney impairment and micro-
albuminuria could then be reduced.1,3  
It was recommended that patients with CKD stages 3 to 
5 should be given a statin to prevent cardiovascular 
complications regardless of lipid level or the need for 
monitoring such level.1,3 Our investigation in the fiscal year of 
2015 found that 40.00% of patients with progression to stage 
4 CKD which was lower than those with no progression 
(58.82%). However, CKD patients with hyperlipidemia were 
still managed based on the guideline for hyperlipidemia 
treatment. As a result, statins were given based on their 
blood lipid levels. Therefore, a relatively low proportion of 
CKD patients stages 3 to 5 receiving a statin. It has been 
found that patients with CKD stages 3 to 5 not receiving a 
statin experienced a higher risk of cardiovascular 
complications than patients with less severe CKD. In patients 
with the last stage of CKD, in particular, the risk of 
cardiovascular complications was 3.4 times of those with no 
statin use (HR = 3.4, 95%CI: 3.1 - 3.8) and the risk of death 
was 5.29 times higher (HR = 5.29, 95% CI: 5.4 - 6.5).19  
Therefore, management protocol of the hospital should be 
revised to agree with the guideline for management of 
patients with CKD.  
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Other complications related to renal failure including 
renal filtration function, anemia, acid-base balance, and bone 
mineral balance. The monitoring of these outcomes among 
individual patients with various CKD stages was different.1 In 
our study, in the fiscal year of 2015, all patients with stage 
3a CKD had been tested for these renal function and 
complications at least once which was in agreement with the 
standard guideline. For patients with CKD stages 3b and 4, 
most of them were they were tested once which did not 
meet the criteria of at least 2 and 3 times of testing per year, 
respectively. Based on these findings, Chok Chai Hospital as 
the supervisor of the health-promoting hospitals could offer a 
complete management for stage 3a CKD patients. The 
hospital could improve the management for patients with 
higher stages of CKD.  
In conclusion, a relatively large proportion of patients 
with CKD stages 3a, 3b and 4 were still treated at the 
health-promoting hospitals. Patients with no progression to 
stage 4 CKD were more likely to be treated according to the 
guidelines than those with the progression. This shortcoming 
was because the service to CKD patients in the year 2015 
was in its relatively early stage according to the CKD clinic 
service plan policy of the Ministry of Public Health issued in 
the year 2014. In addition, no clear management protocol for 
CKD patients had been established. We recommended that, 
based on the policy, identifying CKD patients with an early 
stage should be a focus and a seamless management 
according to standard guidelines such as those of KDIGO 
(2012) and/or the Nephrology Society of Thailand should be 
carried out.1,3 The management and targets should be 
tailored made to individual patient’s needs and hospital’s 
context. Multidiciplinary team should be encouraged and 
facilitated. The ultimate outcomes were knowledge and 
concerns among the patients about how to self-care and 
adhere to the management plan. On the provider side, an 
effective referral and follow-up system to offer an early 
preventive treatment should be fully developed. 
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